Lightpoint signs commercial agreement with HOAM Medical for distribution of SENSEI®, our miniature gamma probe for minimally-invasive and robot-assisted surgery, in South Korea.  

 The brilliant team at UZ Leuven completed their first patient to help us evaluate SENSEI®, our miniature gamma probe for minimally-invasive and robot assisted surgery, in the treatment of prostate cancer.  

 Lightpoint and Telix agree strategic collaboration to explore how Lightpoint's innovative surgical devices and Telix's molecularly-targeted imaging agents can be used together for real-time intra-operative cancer detection.  

 Lightpoint has appointed Graeme Smith as CEO to focus on the commercialization of the company's recently approved miniaturized surgical probe, SENSEI®.  

Lightpoint has secured market clearance in the US, EU, UK and Australia for SENSEI®, the company's new miniature gamma probe for minimally-invasive and robot-assisted cancer surgery,